Infections reported during treatment with BsAb therapy ([A] data from within clinical trials; [B] real-world data with more than 100 patients included) (Continued)
| 7B . | |||||
|---|---|---|---|---|---|
| Infection parameters (%) | BCMA-directed BsAb—teclistamab and elranatamab (n = 200)56 | GPRC5D-directed BsAb—talquetamab (n = 29)56 | BCMA-directed BsAb—teclistamab (n = 123)70 | BCMA-directed BsAb—teclistamab (n = 110)71 | BCMA-directed BsAb—teclistamab (n = 106)72 |
| All grade | 73 | 51 | 54 | 40 | 31 |
| Grades 3-4 | 29 | 26 | 14 | ||
| Infectious death | 9a | a | NR | ||
| Bacterial | 56a | a | NR | 48 | 41 |
| Viral | 38a | a | NR | 45 | 51 |
| Fungal | 5a | a | NR | 7 (3/5 patients PJPc) | 3 |
| Parasites | 1a | a | |||
| IVIG replacement | NRb | b | NR | 43d | 41 |
| 7B . | |||||
|---|---|---|---|---|---|
| Infection parameters (%) | BCMA-directed BsAb—teclistamab and elranatamab (n = 200)56 | GPRC5D-directed BsAb—talquetamab (n = 29)56 | BCMA-directed BsAb—teclistamab (n = 123)70 | BCMA-directed BsAb—teclistamab (n = 110)71 | BCMA-directed BsAb—teclistamab (n = 106)72 |
| All grade | 73 | 51 | 54 | 40 | 31 |
| Grades 3-4 | 29 | 26 | 14 | ||
| Infectious death | 9a | a | NR | ||
| Bacterial | 56a | a | NR | 48 | 41 |
| Viral | 38a | a | NR | 45 | 51 |
| Fungal | 5a | a | NR | 7 (3/5 patients PJPc) | 3 |
| Parasites | 1a | a | |||
| IVIG replacement | NRb | b | NR | 43d | 41 |
Of note, only reports with more than 100 patients are reported.
Not reported separately for BCMA- vs GPRC5D-targeting BsAbs.
Sixty-one percent of infections occurred in patients with HGG and 21% while receiving IVIG; not reported separately for BCMA- vs GPRC5D-targeting BsAbs.
All PJP cases occurred without primary PJP prophylaxis.
The cumulative incidence of infections of grade 3 and higher at 3 and 6 months was 17% in patients receiving IVIG prophylaxis vs 31% and 43%, respectively, without IVIG prophylaxis.
IVIG, intravenous immunoglobulins.
Adapted with permission from Kampouri et al.59